文献速递妇科

依维莫司联合来曲唑治疗复发性雌激素受体阳性高级别卵巢癌的2期试验

Phase 2 trial of everolimus and letrozole in relapsed estrogen receptor-positive high-grade ovarian cancers.
PubMed 文献 · Gynecol Oncol · 2017-04-28

这项2期临床试验评估依维莫司联合来曲唑治疗复发性雌激素受体阳性高级别卵巢癌,主要终点为12周无进展生存比例,45%及以上为阳性结果。19例可评估患者中12周无进展生存率为47%,中位无进展生存期3.9个月,中位总生存期13.0个月,12例(63%)发生至少1次3级或以上不良事件。

要点

  • 19例可评估患者中12周无进展生存率为47%,达到预设阳性阈值。
  • 中位无进展生存期3.9个月,中位总生存期13.0个月。
  • 12例(63%)发生至少1次3级或以上不良事件,毒性可接受。

核心结论

  • 依维莫司联合来曲唑在雌激素受体阳性复发性高级别卵巢癌患者中12周无进展生存率为47%,毒性可接受。
  • 可从卵巢肿瘤活检标本生成患者来源异种移植(PDX)模型。

研究设计与样本

  • 2期临床试验,纳入复发性雌激素受体阳性卵巢癌、输卵管癌或原发性腹膜癌患者,要求有可测量病灶,既往未接受依维莫司或芳香化酶抑制剂治疗,铂耐药和铂敏感肿瘤均纳入。
  • 患者口服依维莫司10mg每日一次和来曲唑2.5mg每日一次。
  • 主要终点为依维莫司联合来曲唑治疗12周后存活且无进展的患者比例,12周无进展生存率45%或以上视为阳性结果。
  • 同时评估从活检标本生成患者来源异种移植(PDX)模型的可行性。
  • 共入组20例患者,19例可评估。

主要发现

  • 19例可评估患者中9例在12周评估时点存活、无进展且仍在治疗中,12周无进展生存率为47%。
  • 中位无进展生存期为3.9个月(95%CI:2.8-11.0)。
  • 中位总生存期为13.0个月。
  • 12例患者(63%)发生至少1次3级或以上不良事件。
  • 17例患者中9例(52.9%)成功生成PDX肿瘤模型。

关键数值与推荐

  • 12周无进展生存率45%或以上视为阳性结果。
  • 患者接受口服依维莫司10mg每日一次和来曲唑2.5mg每日一次。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: We report the results of a phase 2 clinical trial of the combination of everolimus and letrozole in patients with relapsed estrogen receptor-positive high-grade ovarian cancer. The trial's primary endpoint was the proportion of patients alive and progression-free after 12weeks of therapy with the combination of everolimus and letrozole. A 12-week PFS of 45% or greater was considered a positive result. The feasibility of generating patient-derived xenograft (PDX) models from biopsy specimens was also evaluated. METHODS: Eligibility criteria included relapsed estrogen receptor-positive ovarian, fallopian tube or primary peritoneal carcinomas with measurable disease, not previously treated with everolimus or AIs. Both platinum-resistant and sensitive tumors were included. Xenografts were created from image-guided tumor biopsies at baseline. Patients received oral everolimus 10mg daily and letrozole 2.5mg daily. RESULTS: Twenty patients were enrolled, 19 were evaluable. Nine out of 19 were alive, progression-free, and still on treatment at the 12week evaluation time-point (12-week PFS of 47%) with a median PFS of 3.9months (95% CI: 2.8-11.0). The median overall survival was 13.0months. Twelve patients (63%) experienced at least one grade 3 or worse adverse events. PDX tumor engraftment was feasible in the majority of patients (9 out of 17, 52.9%). CONCLUSIONS: The combination of everolimus and letrozole is associated with a promising 47% 12-week PFS rate in patients with ER-positive relapsed high-grade ovarian cancer with acceptable toxicity. PDX tumor models can be generated from biopsies of ovarian tumors.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Colon-Otero G, Weroha SJ, Foster NR, et al. Phase 2 trial of everolimus and letrozole in relapsed estrogen receptor-positive high-grade ovarian cancers. Gynecol Oncol. 2017. PMID: 28461031. doi:10.1016/j.ygyno.2017.04.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。